http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109913425-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-93 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2019-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109913425-B |
| titleOfInvention | Recombinant influenza virus rescue method and application thereof in tumor treatment |
| abstract | The invention discloses a recombinant influenza virus rescue method and application thereof in tumor treatment. The invention provides a method for preparing recombinant virus of coding gene of antibody expressing anti-tumor protein or fusion protein containing the antibody, comprising the following steps: the single-chain coding gene, the heavy chain coding gene and/or the light chain coding gene of the anti-tumor protein antibody are rescued by the virus to obtain the recombinant virus expressing the single chain, the heavy chain and/or the light chain of the anti-tumor protein antibody and other transforming growth factor receptors or the extracellular structural domain coding genes of the receptors. The present invention designs recombinant influenza viruses that express immune checkpoint inhibitory antibodies. Recombinant oncolytic influenza viruses constructed by constructing heavy and light chains encoding immune checkpoint inhibitory antibodies on the HA and NA segments of PR8 virus, respectively, express anti-PD1 antibody, anti-PD-L1 antibody. The oncolytic recombinant influenza virus provided by the invention can kill tumor cells in a targeted manner, has no obvious influence on normal host cells, and can be used for tumor targeted therapy. |
| priorityDate | 2019-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 360.